| Names | |
|---|---|
| Preferred IUPAC name | 4-[5-(4-Pyridinyl)-1H-1,2,4-triazol-3-yl]-2-pyridinecarbonitrile |
| Other names | FYX-051 Topiloric Uriadec |
| Pronunciation | /təˌpɪrɒkˈstəːt/ |
| Identifiers | |
| CAS Number | 577778-58-6 |
| Beilstein Reference | 5792756 |
| ChEBI | CHEBI:77975 |
| ChEMBL | CHEMBL2103872 |
| ChemSpider | 693074 |
| DrugBank | DB12910 |
| ECHA InfoCard | 03bc9673-c9ef-4e7b-89c8-cf3dba409280 |
| EC Number | EC 1.17.3.2 |
| Gmelin Reference | 1585810 |
| KEGG | D09660 |
| MeSH | D000077522 |
| PubChem CID | 25250665 |
| RTECS number | SJ79D8K86Y |
| UNII | N7R6WFG2T3 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C11H8N6O2S |
| Molar mass | 300.24 g/mol |
| Appearance | White to pale yellow powder |
| Odor | Odorless |
| Density | 1.7 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 1.3 |
| Vapor pressure | 6.7E-15 mmHg |
| Acidity (pKa) | 9.2 |
| Basicity (pKb) | 9.53 |
| Magnetic susceptibility (χ) | -11.0e-6 cm^3/mol |
| Refractive index (nD) | 1.663 |
| Dipole moment | 5.6141 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -221.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4637.6 kJ/mol |
| Pharmacology | |
| ATC code | M04AA15 |
| Hazards | |
| Main hazards | Suspected of causing cancer. |
| GHS labelling | GHS labelling of product Topiroxostat: `Warning; H302; H319` |
| Pictograms | CC1=C(C(=O)N(N1)C2=CC=CC=C2)C(=O)N |
| Signal word | Warning |
| Hazard statements | H302, H332 |
| Precautionary statements | P264, P270, P301+P312, P330, P501 |
| Flash point | 119.8±25.6°C |
| Lethal dose or concentration | LD50 oral rat > 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Topiroxostat: "1000 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 120 mg daily |
| IDLH (Immediate danger) | IDLH not established |
| Related compounds | |
| Related compounds | Febuxostat Allopurinol Oxipurinol Tisopurine Y-700 |
| Property | Details | Manufacturer’s Technical Commentary |
|---|---|---|
| Product Name | Topiroxostat | The product is handled internally strictly as Topiroxostat, which aligns with batch records, production reporting, and quality system documentation. Product naming affects endpoint packaging and downline labeling compliance, especially when exporting to destinations where naming conventions are regulated by customs authorities. |
| IUPAC Name | 4-[(3,4-dicyanophenyl)thio]-1-piperazinecarboxamide | Using the established IUPAC name ensures single-identity correspondence throughout synthesis, registration, and trade documentation. Consistency of nomenclature prevents specification errors, which can arise in multi-grade or multi-country shipments as downstream partners may request certificates referencing either the IUPAC or trade names. |
| Chemical Formula | C13H10N6OS | All manufacturing grade records use the molecular formula to match batch composition and for routine calculation of theoretical yield. During in-process control, the molecular formula verifies the identity of intermediates and ensures alignment to the reaction route, especially for grades targeting pharma or regulated applications. |
| Synonyms & Trade Names | FYX-051; Topilux | Distribution under multiple trade names or research synonyms can lead to discrepancies if not aligned in product registration dossiers. The process verification team maintains an internal synonym database to guarantee that all labeling, MSDSs, and technical disclosures reflect the requested name, decreasing the risk of confusion during audits or regulatory checks. |
| HS Code & Customs Classification | 29350090 (heterocyclic compounds with nitrogen hetero-atom[s], other) | Customs classification is based on the dominant chemical structure — in this case, the heterocyclic content and presence of nitrogen atoms justify assignment to 2935 groupings. The precise subcode may vary by region or by end-use declaration, and misclassification in export documents can lead to shipment holds or revalidation requests from import authorities. Operations, compliance, and export documentation teams cooperate to ensure the chosen HS code matches actual product structure and intended market. |
Batch production of Topiroxostat depends on the selected synthetic route, which typically starts with cyanophenyl intermediates and involves thioether bond formation followed by piperazine ring functionalization. Raw material selection focuses on minimizing impurity introduction at the aryl thiolation stage. Process route revision is sometimes dictated by local regulatory demands or downstream customer application, for instance, switching intermediates to suit a low-residual-solvent requirement for pharmaceutical-grade output.
Process analytical technology supports in-process monitoring at multiple control points — especially during cyanation and piperazine coupling steps. Key impurity sources include unreacted starting material and process-specific byproducts. Purification relies on a targeted crystallization or preparative chromatography suite, tuned to the final application specifications. Impurity profile and batch-to-batch consistency are tracked through advanced chromatographic fingerprinting, and the final release standard always matches internal criteria as well as customer or regulatory requirements.
Every change in batch records or documentation—whether it is a naming revision, formula update, or customs code re-validation—is assessed for downstream implications, especially in regulated markets. This direct production experience shapes ongoing improvements in technical support and end-use compliance.
Topiroxostat is processed as a solid, the physical form varies from crystalline powder to fine granules depending on the final grade, micronization conditions, and application use. Color ranges from off-white to pale gray, directly influenced by residual process impurities and crystallization parameters. No distinctive odor is present in any standard grade. Melting point and density profiles reflect the degree of purity and morphology, so final values are specified per batch release documents.
Consistent stability depends on the grade’s residual moisture and process solvents. Topiroxostat resists moderate thermal and photolytic degradation under normal storage; high humidity or excessive heat can promote hydrolysis and colored impurity formation, especially with non-neutral packaging.
Solubility profile shifts with polymorphic state and particle size, which are monitored throughout production. Solution behavior may fluctuate based on pH, temperature, and solvent selection. Preparation of production-scale solutions entails adjustment of agitation, temperature, and order of addition due to limited solubility in water and organic phases. Precipitation or haziness usually points to insufficient pre-filtration or mismatched dilution protocol.
The manufacturer defines main specification ranges according to pharmaceutical or custom industrial standards per order. Key endpoints include assay (HPLC or titration), related substances, moisture, and residual solvent content. Application-driven variants may require tighter limits.
Impurity controls take precedence during process design and batch release. Most process impurities result from raw material trace contaminants or side-reaction pathways linked to overreaction, incomplete neutralization, or prolonged heating. Each batch is screened for known and unknown related substances, process-specific degradants, and non-volatile residues. Purification steps explicitly target threshold values, as set internally or by regulatory submissions.
High-performance liquid chromatography methods, titration, and loss-on-drying are routinely used for lot certification. Testing follows compendial or mutually agreed protocols, with adaptation for high-sensitivity detection if customer or regulatory dossiers specify additional requirements.
Primary raw materials are selectively sourced on lot-traceable contracts to assure consistency in precursor quality. Suitability checks focus on impurity carryover and stability during storage pre-production.
Topiroxostat production employs stepwise condensation and cyclization mechanisms, with process choice determined by cost, waste profile, and environmental controls. Reagent grades and supplier stability impact side-product formation and yield, so direct in-process adjustments are made during scale-up.
Critical control points are in temperature gradients, solvent stripping, and neutralization steps, as these stages heavily influence impurity burden and crystallinity. Recrystallization or filtration is employed based on in-process purity findings. Water and solvent removal strategies vary depending on desired physical grade and downstream performance attributes.
Batch release criteria rest on spectral, chromatographic, and physiochemical conformity, tied to either pharmacopeia guidance or specific client needs. Each release includes comprehensive impurity mapping, solvent residue analysis, and identity confirmation, along with archived retain samples for root cause analysis if deviations occur.
Topiroxostat supports standard aromatic substitution and condensation chemistry under controlled lab or pilot-scale settings. Modification routes focus on amide bond formation, oxidation, or salt formation for formulation development or patent circumvention.
Reaction temperatures, catalyst types, and solvent systems are chosen based on target derivative and regulatory acceptability; scale and waste management restrict some catalyst or solvent options in full-scale production. Downstream purification hinges on isolation efficiency and by-product solubility.
Opportunities for post-synthesis modification include salt formation, esterification, or further heterocycle elaboration. These depend on customer-driven specifications or development of analogs for clinical or analytical research.
Topiroxostat should be stored at controlled temperature and humidity. Light protection limits pigment and impurity drift in photo-labile grades. Some high-purity lots require nitrogen blanketing to minimize oxidative degradation.
Compatibility checks ensure no leaching or polymer migration occurs in primary packaging. Glass and high-density polyethylene serve as standard choices, with secondary containment applied for moisture-sensitive lots.
Shelf life aligns with impurity drift, moisture uptake, and packaging type. Color changes, caking, or new impurity peaks typically flag onset of significant degradation. Stability studies run under ICH or in-house stress protocols back all claims of usable period.
Hazard classification and labeling comply with current GHS guidance for this substance class. Toxicity data originates from published studies and proprietary toxicological screening across acute, chronic, oral, and dermal routes.
Risk statements and precautionary codes reflect actual hazard identification: dust inhalation, skin contact, and accidental ingestion are main occupational risks. All operators use validated engineering controls, PPE, and exposure monitoring per batch and campaign duration.
Exposure limits align with published occupational guidelines or, in their absence, company-specific risk assessments based on animal and in vitro data. Known acute and subacute effects inform training, spill response, and escalation protocols during all handling and transfer operations.
Production output for Topiroxostat continues to reflect both the process route efficiency and the current sourcing landscape for starting materials. Annual manufacturing volumes align directly with downstream demand in both research and commercial segments. Output is constrained or expanded according to the availability of key intermediates, purification bottlenecks, and batch-wise yield repeatability. In recent years, market requirements for tighter impurity profiles and repeated validation batches have influenced both routine batch size and campaign frequency. Higher-purity grades typically require longer cycle times per batch and material-intensive post-processing, affecting net quarterly output.
Factory lead times reflect current campaign scheduling and intermediate stock status. Standard production for commercial-grade Topiroxostat is available within a lead window of several weeks up to a few months, with shorter timelines for regularly scheduled manufacturing slots. Custom or high-assay lots typically require advanced scheduling due to extended purification and analytical release. Minimum order quantity depends on the grade; larger MOQ applies for industrial and API-intermediate lots, while lab and pilot samples can be offered at lower volume packages subject to run-of-batch and sample-approval policy.
Standard-format packaging includes high-density polyethylene drums lined with anti-static liners or, for laboratory grades, sealed aluminum foil pouches within moisture-barrier outer packaging. Package volume will depend on material grade, moisture-sensitivity, and end-user process compatibility. All packaging selection considers handling risk, GMP compliance, and regional regulatory obligations. Custom re-pack is feasible subject to compatibility checks and integrity validation.
Routine commercial shipments are supported under DAP or FOB incoterms, with full documentation reflecting batch traceability and destination regulatory requirements. Thermal control or inert atmosphere shipping is deployed for high-purity or reference-grade lots. Payment terms vary by customer profile, typically net 30 for established downstream partners, with stricter conditions or advance arrangements for new and overseas accounts.
Topiroxostat's cost base is closely tied to both global pricing of APIs and specialty intermediates. Sourcing constraints impact both lead time and base cost. Bulk intermediates sometimes experience price swings due to upstream plant shutdowns or regulatory crackdowns in raw material supply regions. High-purity grades generate additional cost pressure from rigorous impurity isolation and increased labor input during purification. Changes in global energy prices and logistical bottlenecks also exert clear, measurable impact quarterly.
Pricing varies across pharmaceutical, research, and technical grades. Fine differences in impurity profile and lot-specific documentation, such as GMP status or certified reference material, can shift price points significantly. Enhanced analytical dossiers, lot traceability, and full compendial compliance command a clear premium. Packaging format and country-specific compliance certification (e.g., US DMF/CEP/JP DMF) contribute to final landed cost. Customer-driven documentation and regulatory registration support increase fixed overhead per order on qualified product lots.
Demand for Topiroxostat aligns with global gout and hyperuricemia prevalence, with higher market pull in regions of rapid non-communicable disease growth and aging demographics. Supply chain complexity increases where local regulation enforces stricter importation controls on pharmaceutical precursors. Demand in emerging markets shows periodic variability based on hospital tender cycles and generic product launches.
Across the US and EU, the main drivers are regulatory documentation and the volume of finished formulation approvals. Price stability is most notable where long-term supply agreements back finished product manufacture. In Japan, legacy market protection and domestic producer dominance constrain price volatility but require conformance with highly detailed product registration. India and China remain sensitive to upstream cost shocks and shifting domestic environmental policy, affecting both local price points and export volume capacity.
Current outlook anticipates moderate upward pressure on Topiroxostat pricing as regulatory compliance costs rise and raw material volatility continues. Downstream integration pressure from global pharmaceutical consolidation may drive volume-based discounts in key regulated markets but will not offset increased cost for highest-purity grades or lots requiring enhanced regulatory support. Strategic sourcing, alternative process route investment, and leaner campaign scheduling will serve as core mitigation for unpredictable spikes in starting material cost and logistics disruptions, especially through any resurgence of regional export controls or energy price crises.
Price history and forecast modeling draw from proprietary batch cost tracking, regional export-import data aggregation, customer query trends, and rolling third-party market reports. All projections use a combination of weighted raw material index, supply chain incident analysis, and ongoing feedback from downstream QA/QC audits and project RFQs.
Continued realignment of supply partners, heightened scrutiny of cross-border batch documentation, and shifting country-of-origin disclosure requirements influence lot clearance rates and average lead times. Temporary upstream plant closures present real risk for those reliant on single-source intermediates.
Global quality standards for API and intermediate-grade Topiroxostat increasingly reference updated ICH impurity thresholds and audit expectations. Detailed batch traceability and electronic record submissions have become a standard requirement for most regulated markets.
Focus on multi-sourcing, internal qualification of alternative raw intermediate suppliers, and investment in in-process control upgrades allow for greater batch consistency and lower off-spec risk. Campaign planning for high-purity grades prioritizes upstream impurity trending and expanded analytical release testing. Early engagement in customer-driven compliance projects supports smoother regulatory submission and reduces time-to-market for partner drug products.
Topiroxostat serves as a xanthine oxidase inhibitor. The primary field of use centers on pharmaceutical manufacturing, especially in the production of finished dosage forms for gout or hyperuricemia management. The needs of each downstream user—from generic drug formulators to clinical research suppliers—determine the critical attributes of supplied material.
Outside the pharmaceutical sector, research laboratories require analytical grade Topiroxostat for mechanism of action studies, reference standard development, and pharmacokinetic profiling. Any foray into veterinary or specialty chemical synthesis involves bespoke grade requirements.
| Application | Recommended Grade | Comments on Grade Use |
|---|---|---|
| Pharmaceutical API (Human Use) | GMP Grade | Manufactured to comply with ICH Q7; residual solvents, heavy metals, and genotoxic impurities monitored per pharmacopeial or CTD registration dossiers. Batch release depends on full compliance with registered specifications. |
| Formulation Development | Non-GMP Development Grade | Development supply sometimes operates below full GMP, but carries traceability and partial compliance to final specs. Used for phase-appropriate studies; not for final product release. |
| Analytical/Reference Standards | Analytical/Reference Grade | Highly purified with certificate of analysis specifying chromatographic purity and reference identity. Released per customer-defined analytical needs, not for human dosing. |
| Veterinary/Special Synthesis | Technical Grade | Off-specification for human pharma. Parameters reflect end-use sensitivity; some process impurities permissible. Manufactured under ISO or equivalent controls, but not GMP. |
The choice of Topiroxostat grade directly affects levels of organic impurities, residual solvents, polymorphic forms, micronization, and batch-to-batch homogeneity. Pharmaceutical grades typically demand assay and purity at the upper specification, with impurity maxima set by ICH or pharmacopoeial guidelines.
Analytical and reference standards emphasize chromatographic profile, moisture, and identity verification, while technical grades may tolerate higher process-related impurity and variable physical form, based on end-use tolerance and downstream purification steps.
Clarify end use: pharmaceutical final product, preclinical research, method development, or further synthesis. Application details guide raw material sourcing, segregation, and grade assignment.
Assess relevant compliance obligations. For human pharma use, align with region-specific GMP, DMF/CEP submission standards, and impurity documentation. For analytical standards or animal use, map to the corresponding laboratory or ISO standard.
Reference target assay and allowable impurity profile. Early-stage R&D work supports wider impurity range; clinical and commercial API accepts only validated process routes with advanced purification and full impurity profiling. Consider requirements for polymorphic consistency and particle size, if formulation-sensitive.
For large-volume procurement in commercial production, explore available batch sizes and associated economies of scale. Technical and development grades often permit greater flexibility in packaging and lot consolidation. GMP grades require dedicated campaign production and traceability protocols throughout.
Prior to bulk order, request a representative sample batch. Validation enables confirmation of suitability for process fit, analytical compatibility, and regulatory standards. Manufacturer supports documentation package aligned with intended application, supporting technical queries through quality and production departments.
The production of Topiroxostat is supported by a comprehensive quality assurance framework. All current manufacturing lines operate under a third-party audited quality management system that closely aligns with internationally recognized standards. These systems are maintained through documented management routines and recurring system re-assessment. Internal procedures address all stages, from starting material quality verification to packaging and final shipment.
Process validation routines for Topiroxostat follow site-level protocols with a focus on minimizing cross-contamination and batch-to-batch variability. Production logs and batch records are retained for traceability, readily available for qualified customer audits. Inspection results are documented, and deviations are investigated according to the root-cause analysis process maintained on site.
Topiroxostat output batches conform to the specification agreed with each customer at the time of supply. Certifications or product-release documents are batch-specific and grade-dependent. For some supply agreements, additional in-house or third-party analyses can be provided, reflecting different marketplace or regulatory requirements. Kosher, Halal, and other functional certifications may be supported for dedicated grade lines where requested and when raw material provenance allows.
If registration support is needed for pharmaceutical, veterinary, or controlled-use segments, the regulatory affairs team is equipped to provide documentation packs based on internal and external laboratory analyses. The availability and type of certificates such as Certificate of Analysis, GMP compliance reports, and other supporting technical documents depend on the contractual arrangement and application area.
Complete documentation accompanies every shipment of Topiroxostat, including batch-specific analytical reports using validated methods. Where required, detailed impurity profiling, residual solvent data, and heavy metal screening are reported according to customer specifications or the relevant pharmacopeial guidelines governing the grade. Ongoing stability studies support shelf-life claims for applicable grades, using real-time or accelerated conditions as justified by the intended application.
Change control notifications, statement of compliance, and audit reports are part of the customer support portfolio for established accounts with technical cooperation. Customers are encouraged to engage directly with quality or production engineers for technical clarifications or documentation customization requests.
Topiroxostat manufacturing operates on dedicated, monitored production lines with batch reactors and in-line quality assessment. This structure supports both steady long-term programs and projects with dynamic volume needs. The site's capacity adapts to order fluctuations through production scheduling windows and holds flexibility for expedited batch campaigns if coordinated in advance.
Commercial and technical contacts remain accessible during planning and ramp-up stages, allowing for transparency in order confirmation, production slot allocation, and dispatch timing adjustments tied to the customer’s own demand swings.
Process selection for Topiroxostat focuses on raw material continuity, strategic stockholding, and utility redundancy. Secure sourcing relationships ensure that essential intermediates are qualified under dual-vendor principles for critical materials. Finished goods reserves allow for bridging supply interruptions, with minimum and maximum order quantities shaped by application area and delivery mode.
Batch consistency is monitored using trend analyses. Each order triggers a review of critical-to-quality attributes, and release batches only proceed if all internal and mutually-agreed thresholds are met.
Sample requests for technical evaluation are handled by a dedicated applications group. Customers specify quantity, grade, and intended use. The technical team supports selection of a suitable representative batch, coordination of export documentation, and logistics planning. Where required, an accompanying set of analytical documents can be provided.
Sample access policies are reviewed periodically, with a commitment to providing application-relevant material that mirrors commercial-grade characteristics. The technical support team follows up on sample feedback for joint refinement of supply parameters for new projects or application pilots.
Flexible cooperation structures are available for partners seeking agile supply programs, pilot batches, or tailored logistics schedules. Contract manufacturing, consignment inventory, and scheduled call-off agreements form part of the available options, with implementation depending on application sensitivity and customer volume forecast.
For strategic accounts, the business team together with production planning can establish rolling forecasts and dynamic production slots, combined with options for order split, shipping batch optimization, or just-in-time integration to support complex downstream operations.
Requests for documentation adjustment, process adaptation, or regulatory cooperation are reviewed for technical feasibility and controlled through structured change management, with a focus on minimizing disruption to the customer’s formulation, registration, or supply timelines.
Within the industry, Topiroxostat continues to draw researcher attention for its approach to xanthine oxidase inhibition. R&D teams within our own operations have observed growing interest in process optimization to reduce raw material load and energy consumption. Synthetic route selection often revolves around efficiency in controlling by-products and minimizing hazardous intermediates, in line with regulatory scrutiny. Analytical method development for impurity profiling represents another ongoing effort, as downstream clients and regulatory agencies emphasize trace-level differentiated monitoring.
Pharmaceutical innovators are exploring Topiroxostat beyond traditional gout indications, with off-label research and preclinical activity centered on chronic kidney disease and cardiovascular comorbidity risk modulation. Application-specific formulation characteristics, such as particle size distribution and polymorphic form, lead to varying producer requirements. Manufacturing experience suggests that downstream bioavailability targets and tabletability often influence initial crystallization and drying parameters in plant-scale runs.
Primary technical challenges arise from stringent impurity profiles—aromatic amine residuals and nitrosamine risk demand systematic batch-to-batch impurity tracking. Scale-up introduces polysubstituted intermediates, occasionally complicating purification. Adoption of in-line process analytical technologies and improved solid-liquid separation equipment has enabled better control of residual solvents and final product moisture. Batch consistency management relies heavily on automated sampling and robust real-time analytical calibration, which continues to evolve with industry-wide digitalization.
Market demand projections for Topiroxostat tie closely to changes in first-line therapy guidance and originator licensing coverage expiration. At the industrial level, capacity expansions currently favor flexible reactors and modular purification setups, allowing for rapid response to shifts in global regulatory acceptance. Pricing and supply models are sensitive to API grade requirements, with rising preference for lower-residual and micronized forms anticipated in high-compliance markets.
Process intensification is gradually altering production architecture. Operators are incorporating continuous processing steps at pilot scale, targeting higher throughput and lower solvent inventories per unit output. Downstream, solid form screening technologies aid clients working on differentiated formulation strategies, enhancing compatibility with diverse excipient and delivery form profiles.
Environmental compliance is shaping sourcing and waste stream management. Solvent selection increasingly emphasizes low-toxicity and recoverable systems. Internal policy shifts encourage valorization of by-product streams and optimization of energy usage per batch. Supply chain partners focus on origin traceability and documentation of raw material practices, as audit standards tighten and downstream customers request lifecycle impact transparency for each shipment.
Specialists within the technical support team provide direct process feedback and application guidance based on long-term operating data. Solutions for customer-side filtration difficulty or re-crystallization anomalies often involve collaborative troubleshooting, combining plant-analytical insights with customer pilot data. Customization or modification in particle profile, for instance, usually follows in-depth discussion of intended downstream processing methods and stability needs.
Clients experimenting with novel formulations or scale-up often receive hands-on support for solubility and blending integration based on cumulative in-house production and QC results. Documentation supporting process validation and impurity carry-over risk is available to assist with regulatory submissions or technical audits.
Responsiveness to post-shipment technical queries is maintained through a dedicated service platform, linking batch release data and historical in-process QC records with each customer delivery. Return investigations or deviation reports draw on archived analytical records maintained in compliance with both internal standards and external requirements. The commitment to batch traceability ensures transparency from initial raw material intake through to final dispatch, supporting rigorous compliance and customer confidence in each lot released.
Our facility manufactures Topiroxostat from raw material synthesis through final packing. We oversee each production stage and employ process engineers with specialized experience in heterocyclic chemistry and pharmaceutical intermediates. This hands-on approach ensures each lot meets strict batch-to-batch parameters, with material consistency verified by validated analytical methods.
Direct producers supply Topiroxostat primarily to formulators in pharmaceutical manufacturing, especially in active pharmaceutical ingredient (API) preparation. Facilities equipped for scale-up synthesize this compound for subsequent use in chronic gout medications or pipeline formulation programs focusing on xanthine oxidase inhibition. Some industrial research groups work with process development teams in scale transition studies, and the product finds use in chemical R&D settings that need controlled, stable intermediates for drug discovery and biological pathway research.
Manufacturing in-house enables us to maintain rigorous control at all testing and QA points. Each lot undergoes stepwise HPLC, NMR, and mass spectrometry analysis. Chain of custody remains unbroken from raw intermediate to packed final drums. Lot release protocols align with both ICH Q7 and major pharmacopeial demands. Specific impurity limits and allowable residual solvents are constantly audited by internal QC teams.
We handle packaging on-site in controlled cleanroom environments. Typical shipment units include UN-approved fiber drums and high-density double-lined bags. Bulk lots serve plant-scale API batches or contract manufacturing projects, and smaller units support pilot-scale and laboratory evaluation. Inventory buffers help accommodate both contract and spot orders, reducing risk of supply chain interruptions for critical clients. Freight teams prepare documentation for air, sea, or land transport, following regional customs and safety standards for chemical handling.
Our teams assist buyers directly with analytical data, regulatory dossier support, and scalability consultation. Process chemists help transfer synthesis routes to new plants or adapt workflows for specific scale requirements. Documented change control and audit histories back up each delivery, supporting compliance with both internal specifications and local regulatory audits.
Industrial procurement professionals benefit from the traceability offered by direct sourcing. Control over starting materials and final product minimizes risk in regulated markets. Chemical manufacturers choosing integrated partners gain assurance that off-spec risks are addressed at origin. Distributors working with reliable bulk flows reduce delays in high-value pharmaceutical launch cycles. Our logistics and QA staff engage actively with procurement and supply chain teams to anticipate order cycles, align with regulatory changes, and support forecasting.
| Aspect | Description |
|---|---|
| Raw Material Control | Sourced, screened, and processed at origin with full batch traceability |
| Analytical Verification | Comprehensive release testing (HPLC, NMR, MS, elemental analysis) |
| Packaging | Bespoke industrial drum and bag solutions for bulk or pilot-scale |
| Order Flexibility | Stocked lots and made-to-order options to match client requirements |
| Regulatory Support | Technical documentation, validated process data, audit-ready batch records |
Direct manufacturers provide stability and quality for industrial buyers who require certainty in complex supply chains. Each stage is managed onsite, with support that addresses both technical queries and business continuity concerns.
Purity stands at the core of pharmaceutical ingredient reliability, especially for a compound like Topiroxostat. In our plant, the benchmark for Topiroxostat purity traces back to rigorous development trials and industry feedback. Through scaled batch productions and process validation campaigns, we consistently deliver Topiroxostat with an assay (on dried basis) above 99.0%. This figure aligns with or exceeds the expectations of major regulatory pharmacopeias. No material leaves our facility until it passes this requirement, verified by our in-house quality analysts.
Our technical team relies on validated in-house protocols, refined over years of routine and scale-up experience. For Topiroxostat, high performance liquid chromatography (HPLC) remains our gold standard for quantitative assay. We deploy a C18 reversed-phase system, usually with an acetonitrile and phosphate buffer mobile phase. Detection occurs at the compound’s absorption maximum, with all relevant chromatographic parameters audited and standardized by our QA team during each campaign. Each production batch undergoes full release testing in our quality control laboratory.
Beyond assay, we control related substances at every stage. Impurity analysis also leverages HPLC, focusing on specified and total impurities; thresholds typically do not exceed 0.10% for the largest individual impurity and 0.50% for total. These acceptance criteria did not come about by chance; they follow extensive forced degradation studies, root cause investigations, and ongoing stability trials, all performed directly by our R&D center. No shortcuts exist for impurity profiling. As a direct manufacturer, we pay close attention to even minor degradants, updating protocols when new knowledge comes to light from our own batch records.
Moisture often creates unexpected headaches for downstream processors. We measure water content by Karl Fischer titration. This delivers a precise readout, supporting our conservative maximum moisture specification of 0.50%. We also analyze other physical traits, such as melting point, appearance, and residue on ignition—each test method is not a formality, but a foundation for repeatable quality. Our analytical chemists conduct verification on every lot, documenting results for full traceability.
As a manufacturer, the biggest challenge is not just setting high purity specifications, but maintaining them as production volumes increase or as new suppliers of starting materials are qualified. Our response is constant retraining, investment in high-quality reference standards, and process automation. Cross-contamination and batch-to-batch variation receive ongoing scrutiny, with corrective actions implemented quickly based on our own risk assessments. We’ve seen clear benefits from parallel lab and plant investigations: unexplained impurity spikes or yield shortfalls prompt root cause reviews that go all the way back to reaction kinetics or raw material lot differences.
For anyone sourcing Topiroxostat, transparent reporting of the actual analytical data, not just a certificate of analysis, makes a difference when scaling formulations or meeting global regulatory requirements. Our production records and full method validations remain available for partner or customer audits. These checks reflect the seriousness with which we treat each shipment—whether a kilogram sample or a commercial freight lot.
As the direct manufacturer, we adjust and optimize methods based on real process data from our own plant, not just literature or consultant advice. This factory-first approach helps us keep purity standards high and analytical controls rigorous, batch after batch.
Managing the procurement of Topiroxostat at the manufacturing level means looking after every stage, from initial raw material sourcing all the way to final packaging. Every decision made in our process—be it batch size, scheduling, or logistics—ties directly back to the way we set our minimum order quantities and lead times for customers worldwide.
For Topiroxostat, our minimum order quantity is set based on fixed costs of large-scale synthesis, regulatory compliance, and strict quality control. We commit extensive resources to compliance with GMP standards and to maintaining detailed batch records for every production lot. To keep costs reasonable and quality consistent, we’ve aligned production with a minimum batch size of 1 kilogram. Manufacturing any less than this doesn’t fit the industrial workflow and ends up driving per-unit costs far too high, whether for development studies or scale-up supply contracts.
We regularly review production capacity and raw material lead times. Sometimes, for established pharmaceutical companies engaging in scale-up projects or developmental work, we offer samples below our standard MOQ for documented technical assessments. Such requests go through technical validation and strict internal scrutiny. Ultimately, the main driver is efficiency: keeping the reactors fully loaded, minimizing changeover times, and reducing raw material waste, which in turn lets us keep per-unit costs competitive while upholding consistency batch-over-batch.
Lead time for Topiroxostat integrates more than just hours on the production line. Raw materials must arrive validated and passed through incoming QC. Our synthesis involves multiple steps with controlled reaction environments, followed by purification and comprehensive analytical verification before product release. For regular production, lead time from confirmed order and technical alignment to shipment averages between 4 and 6 weeks. For larger order volumes requiring consecutive batches, production scheduling adapts based on plant loading and any given regulatory or logistics review period.
The supply chain has underscored the importance of early demand visibility and clear communication. Unanticipated rush orders or large-scale requirements risk conflict with already scheduled batches, possibly extending lead times. Over the years, we have automated key production steps and invested in logistics partnerships aimed at reducing bottlenecks. Even with modern upgrades, certain steps—such as full stability testing or document sign-off—add several days or more, especially if destination-specific documentation is required.
We constantly evaluate raw material partnerships to buffer against shortages that can harm production timelines. Direct relationships with key chemical suppliers, long-term raw material contracts, and in-house pre-shipment validation help keep lead times predictable. Investments in digital tracking allow our partners to receive reliable delivery schedules and proactive updates before production milestones, reducing unexpected idle time on their end.
For long-term customers, we can set up customized supply agreements, locking in both minimum order quantities and priority scheduling to guarantee steady access across multi-quarter forecasts. Consistent demand forecasting helps us plan reactors, labor, and logistics more accurately. For new projects, we recommend an early technical dialogue with our technical team, focused not only on the specification but also on getting awareness of production windows and logistics risks at the outset.
Meeting minimum order quantities and managing lead times for Topiroxostat aren’t just administrative policies—they come directly from preserving efficiency in chemical manufacturing and providing consistent, compliant product batch after batch. Our production process and experience let us handle the full lifecycle from order receipt to shipment, ensuring that deliveries arrive as scheduled and at the right volume every time.
Shipping pharmaceuticals like Topiroxostat across borders takes more than simply packaging the product securely. Every day in our plant, our quality and regulatory teams guide our shipments through an evolving matrix of global requirements to ensure legal movement and safe arrival at customer sites. Topiroxostat, like many active pharmaceutical ingredients (APIs), faces detailed scrutiny from customs authorities, environmental regulators, and port inspectors. Our job as the manufacturer is not only to respond to those demands, but to anticipate and prepare complete files so our partners face minimal friction down the logistics line.
Topiroxostat falls under both chemical and pharmaceutical controls in many jurisdictions, so our export documents reflect real-world regulatory inspection. Over years of cross-border business, our standard documentation for each Topiroxostat consignment includes a certificate of analysis from our in-house QC lab, safety data sheet in both English and local language as needed, and a country-of-origin declaration. For regulated markets, our team compiles registration, approval, or import licensing documents as local laws dictate, with batch-specific traceability. These papers match original batch numbers and lot codes, not generics or substitutes, directly from our production records.
Strict transport regulations apply to some APIs depending on classification under IATA, IMDG, or ADR. We check each shipment’s classification according to exact specifications and work with freight forwarders certified for chemical shipments. Our logistics supervisors confirm that the packaging, labeling, and spill-recovery instructions match what our safety team has documented and what customs routinely verify. Shipping labels pull information directly from our validated process — including UN codes and hazard pictograms — so that from our loading dock to the destination port, each box carries clear and compliant marking. Contingency, spill, and accident response instructions are always up to date and checked at each shipping stage.
Several countries maintain additional restrictions for pharmaceutical substances, from customs clearance windows to special port documentation. Our compliance team regularly monitors these country-specific requirements, updating our documentation packs based on legislative change or new enforcement trends. We maintain up-to-date dossiers for major export destinations; these include template import permits, translated MSDS, notarized manufacturing licenses, and product-specific trade documents. Every time an order leaves our gate, the export compliance team checks the full set against the latest requirements.
Delays can create major business risk. Over the past year, we have seen customs agencies request batch production records or even original regulatory filings for APIs. Because every step in our Topiroxostat manufacturing flow is traceable in real time, we can supply lot genealogy and batch history to any regulator who asks, typically within the same business day. This direct oversight provides real-world reassurance for our clients — both in regulatory audits and emergency clearances.
We stand behind every Topiroxostat batch with transparent documentation, current regulatory filings, and proven logistics solutions. Our commitment is not only to safe manufacturing, but also to reliable, document-ready international shipping. Should customs or port authorities need additional technical or regulatory files, our compliance response is always prompt, factual, and rooted in validated process data from our own facility.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
